Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026)
Biohaven (BHVN) posted Depreciation & Amortization (CF) of $2.4 million for Q1 2026, down 8.05% sequentially from $2.6 million in Q4 2025, and up 5.34% YoY from $2.2 million in Q1 2025.
Analysis
Biohaven (BHVN) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Biohaven has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 5.34% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 16.03% YoY) and the FY2025 annual result came in at $9.9 million, up 26.31% from the prior year.
- Depreciation & Amortization (CF) eased to $2.4 million in Q1 2026 per BHVN's latest filing, from $2.6 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.1 million in Q3 2025 and troughed at $250000.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.9 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) slumped 49.78% in 2022, then soared 559.6% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $344000.0 in 2022, then jumped by 450.58% to $1.9 million in 2023, then advanced by 29.94% to $2.5 million in 2024, then climbed by 4.55% to $2.6 million in 2025, then dropped by 8.05% to $2.4 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.4 million, $2.6 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 2.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.26 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 2.25 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 344,000.00 |
| Sep 30, 2022 | 377,000.00 |
| Jun 30, 2022 | 415,000.00 |
| Mar 31, 2022 | 250,000.00 |
| Dec 31, 2021 | 685,000.00 |